18-fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 6, 2013, Pages 712-718

  Matsumoto, Ippei ^a   Shirakawa, Sachiyo ^a   Shinzeki, Makoto ^a   Asari, Sadaki ^a   Goto, Tadahiro ^a   Ajiki, Tetsuo ^a   Fukumoto, Takumi ^a   Kitajima, Kazuhiko ^a   Ku, Yonson ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Early Detection; Identification; Metastasis; Pancreatic Cancer

Indexed keywords

CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; AUTOIMMUNE PANCREATITIS; BONE METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; CHRONIC PANCREATITIS; CLINICAL DECISION MAKING; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISTANT METASTASIS; ENDOSCOPE; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PANCREAS ADENOCARCINOMA; PARAAORTIC LYMPH NODE; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; ULTRASOUND SCANNER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CARCINOMA, PANCREATIC DUCTAL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TESTS, ROUTINE; EARLY DIAGNOSIS; ENDOSONOGRAPHY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 84878163016     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.033     Document Type: Article

References (39)

1. Yeo T.P., Hruban R.H., Leach S.D., et al. Pancreatic cancer. Curr Probl Cancer 2002, 26:176-275.
2. Huguet F., Girard N., Guerche C.S., et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009, 27:2269-2277.
3. Schima W., Ba-Ssalamah A., Kölblinger C., et al. Pancreatic adenocarcinoma. Eur Radiol 2007, 17:638-649.
4. Francis I.R. Pancreatic adenocarcinoma: diagnosis and staging using multidetector-row computed tomography (MDCT) and magnetic resonance imaging (MRI). Cancer Imaging 2007, 7:S160-S165.
5. Smith S.L., Basu A., Rae D.M., et al. Preoperative staging accuracy of multidetector computed tomography in pancreatic head adenocarcinoma. Pancreas 2007, 34:180-184.
6. DeWitt J., Devereaux B., Chriswell M., et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004, 141:753-763.
7. Bronstein Y.L., Loyer E.M., Kaur H., et al. Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol 2004, 182:619-623.
8. Fröhlich A., Diederichs C.G., Staib L., et al. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999, 40:250-255.
9. Jimenez R.E., Warshaw A.L., Rattner D.W., et al. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 2000, 135:409-414. discussion, 414-415.
10. Ellsmere J., Mortele K., Sahani D., et al. Does multidetector-row CT eliminate the role of diagnostic laparoscopy in assessing the resectability of pancreatic head adenocarcinoma?. Surg Endosc 2005, 19:369-373.
11. Liu R.C., Traverso L.W. Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 2005, 19:638-642.
12. Abraham S.C., Wilentz R.E., Yeo C.J., et al. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all "chronic pancreatitis"?. Am J Surg Pathol 2003, 27:110-120.
13. Kennedy T., Preczewski L., Stocker S.J., et al. Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: a single-institution experience. Am J Surg 2006, 191:437-441.
14. Zimny M., Bares R., Fass J., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997, 24:678-682.
15. Rose D.M., Delbeke D., Beauchamp R.D., et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999, 229:729-737.
16. Imdahl A., Nitzsche E., Krautmann F., et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999, 86:194-199.
17. Nakamoto Y., Higashi T., Sakahara H., et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000, 89:2547-2554.
18. Sendler A., Avril N., Helmberger H., et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000, 24:1121-1129.
19. Kasperk R.K., Riesener K.P., Wilms K., et al. Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view. World J Surg 2001, 25:1134-1139.
20. Lytras D., Connor S., Bosonnet L., et al. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 2005, 22:55-61. discussion, 62.
21. Wakabayashi H., Nishiyama Y., Otani T., et al. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 2008, 14:64-69.
22. Izuishi K., Yamamoto Y., Sano T., et al. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 2010, 14:1151-1158.
23. Tsutsumi K., Kawamoto H., Hirao K., et al. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Pancreatology 2012, 12:409-416.
24. TNM classification of malignant tumours 2009, Wiley-Blackwell. 7th ed.
25. Seo S., Doi R., Machimoto T., et al. Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. J Hepatobiliary Pancreat Surg 2008, 15:634-639.
26. Satoi S., Yanagimoto H., Toyokawa H., et al. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas 2011, 40:426-432.
27. 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011, 21:2604-2617.
28. Smith C.D., Behrns K.E., van Heerden J.A., et al. Radical pancreatoduodenectomy for misdiagnosed pancreatic mass. Br J Surg 1994, 81:585-589.
29. Kubota K., Yamada K., Yoshioka S., et al. Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F-18 fluorodeoxyglucose. Clin Nucl Med 1992, 17:361-363.
30. Okazaki K., Kawa S., Kamisawa T., et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol 2006, 41:626-631.
31. Shimosegawa T., Chari S.T., Frulloni L., et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011, 40:352-358.
32. Chang W.I., Kim B.J., Lee J.K., et al. The clinical and radiological characteristics of focal mass-forming autoimmune pancreatitis: comparison with chronic pancreatitis and pancreatic cancer. Pancreas 2009, 38:401-408.
33. Wolfson D., Barkin J.S., Chari S.T., et al. Management of pancreatic masses. Pancreas 2005, 31:203-217.
34. Nakamoto Y., Saga T., Ishimori T., et al. FDG-PET of autoimmune-related pancreatitis: preliminary results. Eur J Nucl Med 2000, 27:1835-1838.
35. Ozaki Y., Oguchi K., Hamano H., et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol 2008, 43:144-151.
36. Kamisawa T., Takum K., Anjiki H., et al. FDG-PET/CT findings of autoimmune pancreatitis. Hepatogastroenterology 2010, 57:447-450.
37. Wahl R.L. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 2004, 45(Suppl 1):82S-95S.
38. Kauhanen S.P., Komar G., Seppänen M.P., et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009, 250:957-963.
39. Heinrich S., Goerres G.W., Schäfer M., et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005, 242:235-243.